The race to develop the next generation of medicines just got faster. At least, that is the bet Novo Nordisk is making. The Danish pharmaceutical company announced a strategic partnership with OpenAI ...

Danish drugmaker Novo Nordisk , which has fallen behind Eli Lilly in the immensely lucrative weight-loss drug market, said on ...

Pharmaceutical giant Novo Nordisk is teaming with OpenAI to deploy artificial intelligence in an effort to speed up drug development. The Danish company said the collaborationwill pilot AI to analyze ...

New Delhi: Novo Nordisk, the company behind popular diabetes and obesity drugs – Ozempic and Wegovy, has announced a new partnership with OpenAI to bring artificial intelligence deeper into drug ...

Novo Nordisk NOVO.B3.32%increase; green up pointing triangle said it would work with ChatGPT maker OpenAI on how to leverage artificial intelligence to discover new drugs, the latest AI partnership in ...

Novo Nordisk stock was rising on Tuesday after the Ozempic and Wegovy maker unveiled a partnership with ChatGPT developer OpenAI that it said would speed up drug discovery.

As artificial intelligence continues to rewrite the rules in countless industries, pharma companies are increasingly getting on board—with their AI tie-ups ranging from narrow projects to ...

OpenAI has announced a strategic partnership with pharma giant Novo Nordisk to use advanced AI for drug discovery, including analyzing complex datasets, identifying drug candidates and reducing the ...

Danish pharmaceutical company Novo Nordisk has partnered with OpenAI to support drug research and development. Through the partnership, Novo Nordisk said it plans to deploy advanced artificial ...